ALLYX THERAPEUTICS INC
New Haven, CT · Founded 2018 · CIK 0001865257 · Biotech · Private
Oral small molecule therapeutic for reversing Alzheimer's-related cognitive deficits
allyxthera.com →- Grants
- $4.5M
- 4 awards
- Sector median: 1
- Raised
- $40M
- 4 Form D · May 2026
- 5 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 0 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Cellular Prion Protein Targeting Monoclonal Antibody Antagonist as a Therapy for Alzheimer's Disease | $449,995 | |
| Private capital raised | Form D · SEC | $7,581,493 | |
| Federal grant | Department of Health and Human Services · Phase II · BMS-984923 Non-Clinical Development to Support Phase 2 Trials | $680,220 | |
| Federal grant | Department of Health and Human Services · Phase II · BMS-984923 Non-Clinical Development to Support Phase 2 Trials | $2,019,747 | |
| Private capital raised | Form D · SEC | $2,308,569 | |
| Federal grant | Department of Health and Human Services · Phase II · BMS-984923 Non-Clinical Development to Support Phase 2 Trials | $1,339,527 | |
| Private capital raised | Form D · SEC | $3,324,918 | |
| Private capital raised | Form D · SEC | $26,427,730 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1431 | IT Bio, LLC | — | — |
| 1432 | Jericho Sciences, LLC | — | — |
| 1433 | Starwise Therapeutics LLC | — | — |
| 1434 | ALLYX THERAPEUTICS INC | — | $40M |
| 1435 | BIOLIFE SOLUTIONS INC | — | $10M |
| 1436 | TransChromix LLC | — | — |
| 1437 | ENTERX BIOSCIENCES, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Robert BettigoleDirector
- Stephen BlochDirector · Executive Officer
- Paul FonteyneDirector
- Jennifer GablerExecutive Officer
- Gregory HoDirector
- Kevin RakinDirector
- Timothy SiegertExecutive Officer
- Stephen StrittmatterDirector · Executive Officer
Patents
- Methods Of Use Of (4R,5R)-5-(2-CHLOROPHENYL)-4-(5-(PHENYLETHYNYL)PYRIDIN-3-YL)OXAZOLIDIN-2-ONEapplication
- Methods Of Use Of (4R,5R)-5-(2-CHLOROPHENYL)-4-(5-(PHENYLETHYNYL)PYRIDIN-3-YL)OXAZOLIDIN-2-ONEapplication
- Methods Of Use Of (4R,5R)-5-(2-CHLOROPHENYL)-4-(5-(PHENYLETHYNYL)PYRIDIN-3-YL)OXAZOLIDIN-2-ONEapplication
- MGLUR5 Modulating Compounds, Compositions, And Methods Of Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.